ArticleEBioMedicine2025
Long-term outcomes of patients with pre-existing coronary artery disease after SARS-CoV-2 infection.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical analysis of drug treatment trends for coronary heart disease in China.Frontiers in medicine · 2026Pooled it
- COVID-19 and cardiovascular outcomes in patients with pre-existing hypertension.Journal of human hypertension · 2026Review
- Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care.Critical care (London, England) · 2026Article
- COVID-19 and risk of first-time major depressive disorder in patients without history of psychiatric disorders.BMC psychiatry · 2026Observational
- Effects of COVID-19 pandemic on incidence of asthma exacerbation in an urban population.Scientific reports · 2026Article
- Five-year cardiovascular outcomes following COVID-19-associated carditis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Blood Glucose and Hemoglobin A1c Trends Pre-, During, and Post-COVID-19 Pandemic in an Urban Population.Journal of diabetes · 2026Article
- Cardiovascular sequelae of Long COVID: immune dysregulation inflammation as central drivers.Frontiers in immunology · 2026Review
- Long-Term Cardiovascular and Mortality Risk in Patients with Pre-Existing Arrhythmia Post-SARS-CoV-2 Infection.Diagnostics (Basel, Switzerland) · 2025Article
- Elevated Risk of Long-Term Decline in Left Ventricular Ejection Fraction After COVID-19.Journal of the American Heart Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long-term outcomes of patients with pre-existing coronary artery disease (CAD) after SARS-CoV-2 infection are unknown.
methodsPatients with pre-existing CAD were classified as COVID+ or COVID- based on the polymerase-chain-reaction test in the Montefiore Health System between March 11, 2020, and January 12, 2024. The final cohorts comprised 1380 hospitalised with COVID-19, 1702 non-hospitalised with COVID-19, 7264 contemporary COVID- controls, and 8492 historical controls (January 1, 2016-December 31, 2019). Primary outcomes were all-cause mortality, new-onset congestive heart failure (CHF), myocardial infarction (MI), stroke, and major adverse cardiovascular events (MACE). Cox and Fine-Gray regression models with multivariate adjustment, propensity matching, and inverse probability weighting were applied. Outcomes were also analysed with respect to inflammatory and haematologic biomarkers obtained during acute infection.
findingsCompared to contemporary controls, patients hospitalised with COVID-19, but not patients not hospitalised with COVID-19, had higher future risk of MACE (adjusted HR = 1.58 [1.38, 1.80]), mortality, CHF, MI, and stroke up to four years post-infection (p < 0.05). Analysis using propensity-score matching and inverse probability weighting corroborated the results of multivariate regression. Sensitivity analyses using historical controls and a cohort without excluding early death or loss to follow-up showed consistent results. Among patients hospitalised for COVID-19, elevated neutrophil-to-lymphocyte ratio, ferritin, D-dimer, creatinine, low haemoglobin, and abnormal platelets were associated with increased risk for MACE.
interpretationSevere COVID-19 is associated with long-term cardiovascular risk in patients with pre-existing CAD. Abnormal biomarkers during acute infection were associated with increased risk for MACE. These findings underscore the need for monitoring for cardiovascular risk in patients with pre-existing CAD.
fundingNone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.